Ahmed H. Alasimi

Mr. Ahmed H. Alasimi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
HBHeba M Bintalib
Heba M Bintalib
Munyra AlhotyeMunyra Alhotye
Munyra Alhotye
Jaber AlqahtaniJaber Alqahtani
Jaber Alqahtani
OAOmar A Alqarni
Omar A Alqarni
EAEidan M Alzahrani
Eidan M Alzahrani
Background: Nomophobia is common among students in many healthcare disciplines, and its association with academic performance has been explore before. However, there is no available data on its prevalence and association with academic performance among undergraduate physiotherapy (PT) students in Saudi Arabia. Methods: Between 22 December 2022 and 30 January 2023, a cross-sectional survey was conducted by dissemination using an online platform (Survey Monkey). Results: In total, 806 PT students, with males accounting for 494 (61%), responded to the survey. The prevalence of nomophobia among PT students was 98.4% (793). The mean (±SD) of the total NMP-Q items scores was 49 (± 17), indicating a mild level of nomophobia. Female PT students had significantly higher nomophobia scores than the males (47 (39– 65); 44 (38– 52); (p < 0.001)). Non-smokers had significant higher nomophobia scores than smokers (46 (38– 61); 44 (38– 49); (p = 0.004)). Regarding grade point averages (GPA), the students with a GPA of less than 3.49 had the highest nomophobia score (51 (43– 74); p < 0.001)). Concerning the stage of their studies, bridging students had the highest nomophobia score (51 (34– 76); p = 0.023)). Regarding academic warnings, those who reported no academic warnings had the highest nomophobia score (46 (42– 50); p = 0.023)). Finally, regarding study hours, the students who spent ≥ five hours studying per week had the highest nomophobia score (54 (42– 68); p < 0.001)). Conclusion: Nomophobia is common among PT students, with the majority experiencing a mild level. Being female, non-smoker, and having a higher academic performance were risk factors associated with higher nomophobia levels.

1 January 2024 in Sage Open Medicine
Verified
Journal Article
Open access
RSRayan Siraj
Rayan Siraj
AAAbdulelah M Aldhahir
Abdulelah M Aldhahir
YAYousef R Alzahrani
Yousef R Alzahrani
AAAbdullah A Alqarni
Abdullah A Alqarni
TATurki M Alanazi
Turki M Alanazi
GAGhadeer S Alshammari
Ghadeer S Alshammari
Introduction: Imposter syndrome is common among health disciplinary students, leading to serious consequences. However, the impact of imposter syndrome on self-esteem and quitting intention among respiratory therapy students has not been well researched.Objective: To report on the prevalence of imposter syndrome and assess its impacts on self-esteem and quitting intention among respiratory therapy students in Saudi Arabia.Methods: A nonprobability cross-sectional questionnaire using the Clance Impostor Phenomenon Scale and the Rosenberg Self-Esteem Scale was self-administered and distributed among respiratory therapy students between October 2022 and April 2023. Data analysis was performed using Descriptive and inferential statistics.Results: Of the 1500 respiratory therapy students invited to participate in the study, 901 surveys were completed; and thus, included in the final analysis. Of whom, 92% were presented with imposter syndrome: 44% with moderate, 35% with frequent, and 13% with intense feelings. In addition, 60% of respiratory therapy students and interns experienced low self-esteem, while only 0.5% indicated high self-esteem. More than 50% of the study participants thought about quitting the respiratory therapy program, and 30% have been diagnosed with psychological disorders. Furthermore, there was a significant association between imposter syndrome and low self-esteem, p < 0.001. Factors associated with imposter syndrome and low self-esteem were family income (<0.005) and parents’ education (<0.005), quitting intention (<0.005), and having been diagnosed with psychological disorders (0.005).Conclusion: Imposter syndrome and low self-esteem are prevalent among respiratory therapy students, both of which are associated with considering leaving the respiratory therapy program. Effective interventions should be implemented to ameliorate the symptoms imposter syndrome and low self-esteem; thus, improving the academic experience of respiratory therapy students.

1 March 2024 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
MAMohammed M Alyami
Mohammed M Alyami
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
AAAbdullah A Alqarni
Abdullah A Alqarni
KSKhalid M Salwi
Khalid M Salwi
ASAbdullah M Sarhan
Abdullah M Sarhan
HAHassan Alwafi
Hassan Alwafi
Background: High-flow nasal cannula (HFNC) is an essential non-invasive oxygen therapy in acute respiratory distress syndrome (ARDS) patients. Despite its wide use, research assessing the knowledge, practice, and barriers to using HFNC among respiratory therapists (RT) is lacking. Methods: A cross-sectional questionnaire was conducted among RTs in Saudi Arabia between December 19, 2022, and July 15, 2023. Data were analyzed as means and standard deviation or frequency and percentages. A Chi-square test was used to compare the differences between groups. Results: A total of 1001 RTs completed the online survey. Two-thirds of the respondents 659 (65.8%) had received training in using HFNC and 785 (78.4%) had used HFNC in clinical settings. The top conditions for HFNC indication were COVID-19 (78%), post-extubation (65%), and do-not-intubate patients (64%). Participants strongly agreed that helping maintain conversation and eating abilities (32.95%) and improving shortness of breath (34.1%) were advantages of HFNC. Surprisingly, 568 (57%) of RT staff did not follow a protocol for HFNC with ARDS patients. When starting HFNC, 40.2% of the participants started with FiO2 of 61% to 80%. Additionally, high percentages of RT staff started with a flow rate between 30 L/minute and 40 L/minute (40.6%) and a temperature of 37°C (57.7%). When weaning ARDS patients, 482 (48.1%) recommended first reducing gas flow by 5– 10 L/minute every two to four hours. Moreover, 549 (54.8%) believed that ARDS patients could be disconnected from HFNC if they achieved a flow rate of < 20 L/minute and FiO2 of < 35%. Lack of knowledge was the most common challenge concerning HFNC implementation. Conclusion: The findings revealed nuanced applications marked by significant endorsement in certain clinical scenarios and a lack of protocol adherence, underscoring the need for uniform, evidence-based guidelines and enhanced training for RTs. Addressing these challenges is pivotal to optimizing the benefits of HFNC across varied clinical contexts.

22 November 2023 in Heliyon
Verified
Journal Article
Open access
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
AAAbdullah A Alqarni
Abdullah A Alqarni
MAMohammed A Almeshari
Mohammed A Almeshari
NANowaf Y. Alobaidi
Nowaf Y. Alobaidi
OAOmar A. Alqarni
Omar A. Alqarni
HAHassan Alwafi
Hassan Alwafi
Limited data is available on awareness and clinical management of the airway pressure release ventilation (APRV) mode of ventilation for acute respiratory distress syndrome (ARDS) patients among physicians who work at in adult critical areas. This study aimed to assess the knowledge and current practice of using APRV mode with ARDS patients and identify barriers to not using this mode of ventilation among physicians who work in adult critical areas in Saudi Arabia. Between November 2022 and April 2023, a cross-sectional online survey was disseminated to physicians who work in adult critical areas in Saudi Arabia. The characteristics of the respondents were analyzed using descriptive statistics. Percentages and frequencies were used to report categorical variables. Overall, 498 physicians responded to the online survey. All responders (498, 100 %) reported that APRV is indicated in patients with ARDS, but 260 (52.2 %) did not know if there was an institutionally approved APRV protocol. Prone positioning was the highest recommended intervention by 164 (33.0 %) when a conventional MV failed to improve oxygenation in patients with ARDS. 136 (27.3 %) responders stated that the P-high should be set equal to the plateau pressure on a conventional ventilator while 198 (39.8 %) said that P-low should be 0 cmH2O. Almost half of (229, 46.0 %) responders stated that the T-high should be set between 4 and 6 s, while 286 (57.4 %) said that the T-low should be set at 0.4–0.8 s. The maximum allowed tidal volume during the release phase should be 4–6 ml/kg. Moreover, just over half (257, 51.6 %) believed that the maximum allowed P-high setting should be 35 cmH2O. One third of the responders (171, 34.3 %) stated that when weaning patients with ARDS while in APRV mode, the P-high should be reduced gradually to reach a target of 10 cmH2O. However, 284 (36.9 %) thought that the T-high should be gradually increased to reach a target of 10 s. Most responders (331, 66.5 %) felt that the criteria to switch the patient to CPAP would be to have an FiO2 ≤ 0.4, P-high ≤10 cm H2O, and T-high ≥10 s. Lack of training has been the most common barrier to not using APRV by 388 (77.9 %). There is a lack of consensus on the use of APRV mode, probably due to several barriers. While there were some agreements on the management of ventilation and oxygenation, there were variations in the selection of the initial setting of APRV. Education, training, and the presence of standardized protocols may help to provide better management.

18 September 2025 in Health Science Reports
Verified
Journal Article
Open access
MAMohammed M. Alyami
Mohammed M. Alyami
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
AAAbdullah A. Alqarni
Abdullah A. Alqarni
AAAmal A. Alqahtani
Amal A. Alqahtani
SHSara M. Homadi
Sara M. Homadi
HAHassan Alwafi
Hassan Alwafi
Background and Aims: High‐flow nasal cannula (HFNC) is increasingly utilized in clinical practice; however, the perspectives of physicians on its use and associated barriers in managing acute respiratory distress syndrome (ARDS) in Saudi Arabia remain unexplored. This study aims to evaluate HFNC practices and identify the barriers faced by ICU and respiratory physicians in utilizing HFNC for ARDS patients. Methods: A cross‐sectional survey was distributed between December 22, 2022, and July 15, 2023, to respiratory and ICU physicians in Saudi Arabia. Data are presented as frequencies and percentages. Results: A total of 987 responses were analyzed, revealing that physicians perceive HFNC as beneficial for relieving shortness of breath (686, or 69.5%), helping with speech and eating (649, or 65.8%), and potentially preventing intubation (629, or 63.7%). In terms of HFNC practice, 445 respondents (45.1%) reported that its use is governed by institutional protocols, while 679 (68.8%) indicated that the decision to initiate therapy is made by physicians. Additionally, 458 (46.4%) stated that a flow rate of ≥ 15 L/min is necessary to start HFNC therapy. When considering initial settings, nearly half (455, or 46.09%) chose a fraction of inspired oxygen (FiO 2 ) between 61%–80%, 442 (44.8%) chose a flow between 30 and 40 L/min, and 476 (48.23%) chose a temperature of 34°C. Reducing gas flow by 5–10 L/min every two to 4 h was the most appropriate way of weaning, according to 407 (41.24%), and both FiO 2 < 35% and gas flow < 20 L/min should be achieved to disconnect HFNC therapy. Lack of knowledge about HFNC therapy was the most commonly reported barrier (494, or 50.1%). Conclusion: Physicians demonstrated a comprehensive understanding of the potential benefits associated with HFNC therapy. However, variations in initial settings and the absence of standardized guidelines present significant challenges to its optimal application in patients with ARDS.

15 July 2026 in Pulmonary Circulation
Verified
Journal Article
Open access
AAAbdullah A Alqarni
Abdullah A Alqarni
RARawan H. Aljedani
Rawan H. Aljedani
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
AAAhmed H. Alasimi
Ahmed H. Alasimi
AAAbdulkareem A. AlGarni
Abdulkareem A. AlGarni
HAHassan Alwafi
Hassan Alwafi
Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct and potentially curable form of pulmonary hypertension; however, a substantial proportion of patients remain inoperable or experience persistent or recurrent disease. Pharmacological therapies targeting the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) pathway have emerged as promising treatment options. Therefore, this systematic review aimed to comprehensively evaluate the therapeutic efficacy of drugs targeting the NO–sGC–cGMP pathway on clinical outcomes in patients with CTEPH. We conducted a comprehensive search of electronic databases, including Embase, MEDLINE, Cochrane Library, and Scopus databases from inception to December 1, 2025. Studies involving adult patients with confirmed CTEPH receiving NO–sGC–cGMP pathway‐targeted therapies were included. Exclusion criteria encompassed case reports, systematic reviews, review articles, conference abstracts with no full text (since they were not peer‐reviewed), non‐full‐text articles, non‐English manuscripts, opinion articles, and book chapters. Risk of bias was assessed using the Cochrane RoB 2 tool and the Newcastle–Ottawa Scale. A total of 23 studies involving 2815 patients were included. The most frequently investigated agents were riociguat and sildenafil. Fourteen of 15 studies demonstrated significant improvements in exercise capacity, with consistent findings reported in major trials such as CHEST‐1 and its long‐term extension, CHEST‐2. All 16 studies assessing pulmonary hemodynamics reported significant improvements in mPAP, PVR, and CO. Additionally, 12 studies showed reductions in NT‐proBNP levels and improvements in WHO‐FC, indicating enhanced functional status. Quality of life was assessed in two studies, both of which demonstrated favorable outcomes. Furthermore, three studies reported improvements in right ventricular function and risk stratification. Pharmacological agents targeting the NO–sGC–cGMP pathway, particularly riociguat and sildenafil, demonstrate consistent improvements in exercise capacity, pulmonary hemodynamics, functional status, and biomarkers in patients with CTEPH. These findings support their role as effective therapeutic options, especially in inoperable or persistent CTEPH. Nevertheless, further large‐scale, high‐quality randomized controlled trials are warranted to strengthen the evidence base and optimize treatment strategies. Systematic review registration: CRD42024510274, https://www.crd.york.ac.uk/PROSPERO/view/CRD42024510274 .